Influence of membrane fluidity on human immunodeficiency virus type 1 entry
- 1. Department of Medical Virology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556 (Japan)
- 2. Department of Microbiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556 (Japan)
Description
For penetration of human immunodeficiency virus type 1 (HIV-1), formation of fusion-pores might be required for accumulating critical numbers of fusion-activated gp41, followed by multiple-site binding of gp120 with receptors, with the help of fluidization of the plasma membrane and viral envelope. Correlation between HIV-1 infectivity and fluidity was observed by treatment of fluidity-modulators, indicating that infectivity was dependent on fluidity. A 5% decrease in fluidity suppressed the HIV-1 infectivity by 56%. Contrarily, a 5% increase in fluidity augmented the infectivity by 2.4-fold. An increased temperature of 40 deg C or treatment of 0.2% xylocaine after viral adsorption at room temperature enhanced the infectivity by 2.6- and 1.5-fold, respectively. These were inhibited by anti-CXCR4 peptide, implying that multiple-site binding was accelerated at 40 deg C or by xylocaine. Thus, fluidity of both the plasma membrane and viral envelope was required to form the fusion-pore and to complete the entry of HIV-1
Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2005.02.007;
- PII
- S0006-291X(05)00249-4;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 329
- Journal Issue
- 2
- Journal Page Range
- p. 480-486
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 36073749
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- AIDS VIRUS; FLUIDIZATION; INFECTIVITY; MEMBRANES; PEPTIDES; RECEPTORS
- Descriptors DEC
- MEMBRANE PROTEINS; MICROORGANISMS; ORGANIC COMPOUNDS; PARASITES; PROTEINS; VIRUSES
Optional Information
- Copyright
- Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.